切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2019, Vol. 08 ›› Issue (04) : 362 -365. doi: 10.3877/cma.j.issn.2095-3232.2019.04.019

所属专题: 文献

临床研究

FibroTouch联合AST-血小板比值指数在肝硬化门静脉高压症诊断中的应用
熊志娇1, 范红顺1, 朱先女1, 沈莉华1, 刘莹2,()   
  1. 1. 512028 广东韶关,粤北第二人民医院肝病科
    2. 510630 广州,中山大学附属第三医院感染科
  • 收稿日期:2019-04-23 出版日期:2019-08-10
  • 通信作者: 刘莹
  • 基金资助:
    广东省科技计划项目(2016A020215221,2017A030313620)

Application of FibroTouch combined with AST to platelet ratio index in diagnosis of portal hypertension in patients with hepatic cirrhosis

Zhijiao Xiong1, Hongshun Fan1, Xiannv Zhu1, Lihua Shen1, Ying Liu2,()   

  1. 1. Department of Liver Diseases, the Second Yuebei People's Hospital, Shaoguan 512028, China
    2. Department of Infection, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2019-04-23 Published:2019-08-10
  • Corresponding author: Ying Liu
  • About author:
    Corresponding author: Liu Ying, Email:
引用本文:

熊志娇, 范红顺, 朱先女, 沈莉华, 刘莹. FibroTouch联合AST-血小板比值指数在肝硬化门静脉高压症诊断中的应用[J]. 中华肝脏外科手术学电子杂志, 2019, 08(04): 362-365.

Zhijiao Xiong, Hongshun Fan, Xiannv Zhu, Lihua Shen, Ying Liu. Application of FibroTouch combined with AST to platelet ratio index in diagnosis of portal hypertension in patients with hepatic cirrhosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2019, 08(04): 362-365.

目的

探讨无创肝纤维化检测系统(FibroTouch)联合AST-血小板比值指数(APRI)检测对肝硬化门静脉高压症的诊断价值。

方法

本研究对象为2016年1月至2018年6月在粤北第二人民医院接受诊治的90例乙型病毒性肝炎(乙肝)后肝硬化患者和慢性乙肝患者。患者均签署知情同意书,符合医学伦理学规定。将患者分为肝硬化组和慢乙肝组,每组各45例。其中肝硬化组男31例,女14例;年龄35~78岁,中位年龄52岁。慢乙肝组男28例,女17例,年龄28~76岁,中位年龄51岁。采用FibroTouch检测肝脏硬度值(LSM),计算APRI,彩色多普勒超声测量门静脉直径,胃镜检查食管静脉曲张程度。检测指标比较采用单因素方差分析或t检验,相关性分析采用Spearman秩相关。

结果

肝硬化组LSM和APRI分别为(22±7)kPa、2.01±0.35,明显大于慢乙肝组的(8±3)kPa、0.80±0.26(t=3.586,7.305;P<0.05)。肝硬化患者门静脉直径及食管静脉曲张程度与LSM和APRI均成正相关(rs=0.527,0.701和0.803,0.605;P<0.05)。

结论

FibroTouch联合APRI检测可较准确地诊断肝硬化门静脉高压症,具有经济、无创、可重复使用优势,且可动态监测门静脉高压症情况。

Objective

To explore the value of non-invasive liver fibrosis detection system (FibroTouch) combined with aspartate aminotransferase to platelet ratio index (APRI) in the diagnosis of portal hypertension induced by liver cirrhosis.

Methods

90 patients diagnosed with liver cirrhosis induced by viral hepatitis B or chronic hepatitis B treated in the Second Yuebei People's Hospital from January 2016 to June 2018 were recruited. The informed consents of all patients were obtained and the local ethical committee approval was received. The patients were divided into the liver cirrhosis group (n=45) and chronic hepatitis B group (n=45). In the liver cirrhosis group, 31 cases were male and 14 female, aged 35-78 years with a median age of 52 years. In the chronic hepatitis B group, 28 patients were male and 17 female, aged 28-76 years with a median age of 51 years. Liver stiffness measurement (LSM) was measured with FibroTouch. APRI was calculated. The diameter of portal vein were measured by color Doppler ultrasound. The severity of esophageal varices was assessed by gastroscopy. All parameters were statistically analyzed by one-way ANOVA or t test. Correlation analysis was conducted by Spearman's rank correlation analysis.

Results

The LSM and APRI in liver cirrhosis group were (22±7) kPa and 2.01±0.35, significantly higher than (8±3) kPa and 0.80±0.26 in chronic hepatitis B group (t=3.586,7.305; P<0.05). The portal vein diameter and esophageal varices in patients with liver cirrhosis were positively correlated with LSM and APRI (rs=0.527, 0.701 and 0.803, 0.605; P<0.05).

Conclusions

The combination of FibroTouch and APRI can accurately diagnose portal hypertension induced by liver cirrhosis, which is economical, non-invasive and reusable, and can dynamically monitor the portal hypertension.

表1 肝硬化患者门静脉直径与LSM、APRI的关系(±s
表2 肝硬化患者食管胃底静脉曲张程度与LSM、APRI的关系(±s
[1]
中华医学会外科学分会门静脉高压学组.肝硬化门静脉高压症食管、胃底静脉曲张破裂出血的诊治共识(2015版)[J].中华外科杂志,2015, 53(12):917-921.
[2]
Hwang JH, Shergill AK, Acosta RD, et a1. The role of endoscopy in the management of variceal hemorrhage[J]. Gastrointest Endosc, 2014, 80(2):221-227.
[3]
Manohar TP, Patil V, Salkar HR. Combination of non-endoscopic parameters as predictors of large esophageal varices[J]. Trop Gastroenterol, 2014, 35(3):173-179.
[4]
中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版)[J].中华肝脏病杂志,2015, 23(12): 888-905.
[5]
蒋志凌,陈旭平,付冰,等.肝硬化食管静脉曲张程度门脾静脉内径及Child-Pugh分级的关系[J].华西医学,2011, 26(2):187-188.
[6]
中华医学会消化内镜学分会食管胃静脉曲张学组.消化道静脉曲张及出血的内镜诊断和治疗规范试行方案(2009年)[J].中华消化内镜杂志,2010, 27(1):1-4.
[7]
Intagliata NM, Caldwell SH, Poete RJ, et al. Prediction of bleeding in cirrhosis patients: is the forecast any chearer?[J]. Hepatology, 2016, 64(3):989-990.
[8]
阳绍军.肝硬化门脉血管B超检查对判断食管静脉曲张的价值探讨[J].山西医药杂志,2018, 47(15):1770-1772.
[9]
何创业,吕勇,陈辉,等.瞬时弹性成像技术在诊断特发性门静脉高压症中的价值[J].中华肝脏病杂志,2018, 26(4):310-312.
[10]
陈志敏,应若素,陈铿,等.瞬时弹性扫描仪检测肝脏硬度评估肝硬化门脉高压症[J].中华生物医学工程杂志,2016, 22(2):131-134.
[11]
肝脏硬度评估小组.瞬时弹性成像技术诊断肝纤维化专家意见[J].中华肝脏病杂志,2013, 21(6):420-424.
[12]
Poynard T, Pham T, Perazzo H, et a1. Real-time shear wave versus transient elastography for predicting fibrosis: applicabiliy, and impact of inflammation and steatosis. a non-invasive comparison[J]. PLoS One, 2016, 11(10):e0163276.
[13]
欧晓娟,王晓明,吴晓宁,等.FibroTouch与FibroScan在慢性乙型肝炎患者肝纤维化评估中的比较[J].中华肝脏病杂志,2015, 23(2):103-106.
[14]
陈高峰,平键,顾宏图,等.慢性乙型肝炎患者FibroTouch和FibroScan检测肝脏硬度与肝组织学Ishak纤维化评分的相关性分析[J].中华肝脏病杂志,2017, 25(2):145-150.
[15]
Petersen JR, Stevenson HL, Kasturi KS, et al. Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosistests to detect significant fibrosis due to chronic hepatitis C [J]. J Clin Gastroenterol, 2014, 48(4):370-376.
[16]
Procopet B, Tantau M, Bureau C. Are there any alternative methods to hepatic venous pressure gradient in portal hypertension assessment?[J]. J Gastrointestin Liver Dis, 2013, 22(1):73-78.
[17]
谢冬英,谢仕斌,李勇忠,等.肝纤维化与门静脉、脾静脉直径、脾脏大小及血细胞计数的关系[J].中华消化杂志,2000, 20(5): 308-310.
[18]
张卓恒,闫媛媛,史海宏,等.FibroTouch、ARFI及血清学指标对慢性乙型肝炎患者肝纤维化程度的诊断价值比较[J].肝脏,2018, 23(6):529-531.
[19]
胡娜,欧晓娟.FibroTouch评价脾脏硬度与肝硬化门静脉高压参数的相关性分析[J/CD].中华临床医师杂志(电子版),2016, 10(4):468-470.
[20]
王帅,张成,张帆,等.FibroScan和APRI对肝硬化食管胃底静脉曲张程度的预测价值[J].中华肝脏病杂志,2018, 26(5):342-346.
[1] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[2] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[3] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[4] 李芳, 孙海云. 风险因素护理干预对合并失代偿性肝硬化的腹股沟疝患者Lichtenstein术围手术期应用效果[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(04): 477-480.
[5] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[6] 韩宇, 张武, 李安琪, 陈文颖, 谢斯栋. MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 669-673.
[7] 赫嵘, 贾哲, 张珂, 李代京, 张萌, 蒋力. 基于PSM分析腹腔镜肝切除联合Hassab术治疗合并门静脉高压症肝癌疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 376-383.
[8] 李勇, 兰川, 吴斌, 张光年, 李敬东. 术前血小板-白蛋白评分对肝硬化肝癌术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 412-416.
[9] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[10] 杨林青, 任松, 纪泛扑, 张健, 蒋安, 张丽, 安鹏, 王林, 李宗芳. 揿针疗法对门静脉高压症脾切除断流术后胃肠功能的调节作用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 322-326.
[11] 秦维, 王丹, 孙玉, 霍玉玲, 祝素平, 郑艳丽, 薛瑞. 血清层粘连蛋白、Ⅳ型胶原蛋白对代偿期肝硬化食管胃静脉曲张出血的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 447-451.
[12] 张雯, 宋牡丹, 邓雪婷, 张云. 强化营养支持辅助奥曲肽治疗肝硬化合并食管胃底静脉曲张破裂出血的疗效及再出血危险因素[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 456-460.
[13] 朱翔宇, 王建美, 张辉, 叶红英. 无创左心室压力-应变循环技术在左心室功能参数与肝硬化的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 494-498.
[14] 郭亮亮, 邱珊珊, 钟萍, 赵心恺. 血小板-白蛋白-胆红素评分对肝硬化上消化道出血的诊断价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 216-219.
[15] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
阅读次数
全文


摘要